Homozygous Familial Hypercholesterolemia Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment. The secondary objectives of the study are: - To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein [Apo] A-1 and B, non-high-density lipoprotein cholesterol [non-HDL-C], total-cholesterol [TC], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides [TG]) in participants with HoFH - To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH - To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH - To assess the potential development of anti-drug (alirocumab) antibodies
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04031742 -
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06009393 -
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 2 | |
| Recruiting |
NCT06125847 -
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
|
Early Phase 1 | |
| Completed |
NCT01878604 -
Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
|
N/A | |
| Completed |
NCT01412034 -
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
|
Phase 2 | |
| Withdrawn |
NCT02765841 -
Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy
|
Phase 3 | |
| Completed |
NCT03933293 -
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
|
Phase 2 | |
| Completed |
NCT00704535 -
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
|
||
| Recruiting |
NCT02135705 -
LOWER: Lomitapide Observational Worldwide Evaluation Registry
|
||
| Completed |
NCT03409744 -
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT04233918 -
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Withdrawn |
NCT02399852 -
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
|
N/A | |
| Terminated |
NCT01841684 -
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
|
Phase 3 | |
| Recruiting |
NCT01109368 -
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
|
||
| Completed |
NCT01556906 -
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
|
Phase 2 | |
| Active, not recruiting |
NCT03135184 -
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
|
N/A | |
| Recruiting |
NCT04815005 -
HoFH, the International Clinical Collaborators Registry
|
||
| Completed |
NCT03399786 -
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT03851705 -
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 3 | |
| Completed |
NCT02265952 -
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 2 |